Price Chart

Executive Summary

Avalo Therapeutics filed an 8-K reporting that stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan at the 2026 annual meeting. The plan authorizes up to 961,608 shares for issuance, with annual evergreen increases of up to 4,000,000 shares or 1% of outstanding shares through 2036. This is a routine compensatory plan amendment with no material financial impact.

Key Facts

• Stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan on June 2, 2026.
• The plan authorizes an aggregate of 961,608 shares of common stock for issuance.
• Annual evergreen increases begin January 1, 2027 through January 1, 2036, up to the lesser of 4,000,000 shares or 1% of outstanding shares (including Series C Preferred on as-converted basis) plus prefunded warrants.
• Purchase price is at least 85% of the lower of fair market value on the offering date or purchase date.
• All seven director nominees were elected with overwhelming support (over 99% of votes cast for each).
• Ratification of Ernst & Young LLP as independent auditor passed with 22,513,332 votes for, 153,320 against.
• The ESPP approval received 14,513,683 votes for, 6,588,576 against, and 1,569,682 broker non-votes.

Financial Impact

Up to 961,608 shares initially authorized, with annual evergreen increases up to 4,000,000 shares or 1% of outstanding shares. At current market cap of $689M, maximum annual dilution from evergreen is approximately 1% of shares outstanding.

Risk Factors

• Potential dilution from annual evergreen increases up to 1% of outstanding shares per year through 2036.
• ESPP approval had notable opposition (6.6M votes against vs 14.5M for), suggesting some shareholder dissent on compensation structure.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status